Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
From tax breaks to Obamacare repeal, medtech companies are likely due to experience major changes under President Donald Trump. The situation, though, remains unpredictable.
“I don’t think that there has been a scenario, not since I’ve been a professional and in politics, where we really know so little about exactly what the key priorities are that are going to impact our industry,” Shaye Mandle, president and CEO of the Medical Alley Association in Minnesota, recently told MDO. Read more
A federal judge in Colorado ruled earlier this month that Ceramtec cannot trademark its ceramic hip implants’ pink color, after the company wrote a cease and desist letter to Coorstek Medical in 2014 over its competing CeraSurf device.
Forth Worth, Texas-based Coorstek’s CeraSurf device is made with ceramic material that uses chromium oxide, which provides hardness and toughness to the device and gives it a pink color. In February last year, the FDA cleared CeraSurf to be used in hip implants and declared the material to be substantially equivalent to predicate systems including Ceramtec’s Biolox Delta material. Read more
CardioFocus said today it launched a clinical trial of its next-generation HeartLight Excalibur balloon device designed for pulmonary vein isolation procedures.
The Marlborough, Mass.-based company said the next-gen device incorporates the balloon design from its HeartLight endoscopic ablation system alongside a new advanced feature set intended to improve speed and the magnitude of target tissue contact during procedures. Read more
A study conducted by a team of U.S. researchers found that financial ties between researchers and the companies that make the drugs they are studying are independently associated with positive trial results. The team’s work was published in The BMJ this week.
The study was observational, so the results can’t be used to draw concrete conclusions. But the authors write that since industry and academia collaborate to advance many new treatments, “more thought needs to be given to the roles that investigators, policy makers, and journal editors can play in ensuring the credibility of the evidence base.” Read more
A federal judge in Boston yesterday added another $21 million to the judgment against Neovasc in a trade secret spat with Edwards Lifesciences subsidiary CardiAQ Valve that’s already cost Neovasc some $91 million.
A jury in May awarded $70 million to CardiAQ after finding that Neovasc misappropriated trade secrets in developing its Tiara transcatheter mitral valve replacement device. Edwards inherited the lawsuit when it acquired CardiAQ Valve for $400 million in August 2014. Read more